Clinical trials: GERD - PPI Responders
GERD - PPI Non-responders
Effect of Baclofen in Management of Patients With Gastroesophageal Reflux Disease Symptoms
The goal of this clinical trial is to assess the effect of using baclofen along with conventional treatment in improving GERD symptoms.
- Trial name
- NCT07063576
- Testing
- Baclofen 10mg
- Where
- Bangladesh
- Volunteers
- 60 people
- Sponsor
- Adnan Imtiaj Rahul
Gastroesophageal Reflux Disease, Heartburn
Do Acid Sensing Ion Channels Contribute to Heartburn?
The purpose of this research study is to learn about whether treating the esophagus with amiloride reduces either the frequency or the time to onset of acid-induced heartburn in patients with nonerosive reflux disease.
- Trial name
- NCT01095133
- Testing
- Amiloride
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
GERD - PPI Responders, GERD - PPI Non-responders
Acid Pocket: Position and Aspiration
Gastroesophageal reflux disease (GERD) is a very common condition affecting up to 30% of adults. To date, therapy consists of powerful acid suppression with proton pump inhibitors (PPI).
- Conditions
- GERD - PPI Responders, GERD - PPI Non-responders, Barrett Esophagus, Healthy Volunteers
- Trial name
- NCT02199002
- Testing
- multi-pH-impedance manometry catheter
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- KU Leuven
Gastro Esophageal Reflux
Effectiveness of Physiologic Testing in PPI Non-Responders
The prevalence of GERD is estimated to be as high as 20% in the US, and up to 50% remain symptomatic on proton pump inhibitor (PPI) therapy.
- Trial name
- NCT03202537
- Testing
- dexlansoprazole
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Northwestern University
Gastroesophageal Reflux Disease (GERD)
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI…
- Trial name
- REMAIN (NCT00795093)
- Where
- 53 sites in United States
- Volunteers
- 552 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors
- Trial name
- NCT00810485
- Testing
- ADX10059
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 298 people
- Sponsor
- Addex Pharma S.A.
Gastroesophageal Reflux Disease
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to evaluate efficacy and safety of arbaclofen placarbil (XP19986) versus placebo as adjunctive therapy in subjects with troublesome GERD symptoms despite therapy with approved doses of a Proton Pump…
- Trial name
- NCT00978016
- Testing
- arbaclofen placarbil-Cohort 1, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3
- Where
- 64 sites in United States, Canada
- Volunteers
- 460 people
- Sponsor
- XenoPort, Inc.
Gastroesophageal Reflux
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.
- Trial name
- NCT05556824
- Testing
- MHS-1031
- Where
- 18 sites in United States
- Volunteers
- 255 people
- Sponsor
- Microbiome Health Sciences
Gastroesophageal Reflux Disease
Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)
To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to esomeprazole 20mg (standard proton pump inhibitor [PPI] treatment), in subjects with…
- Trial name
- NCT00730665
- Testing
- PF-00885706, Esomeprazole
- Where
- 38 sites in Belgium, Brazil and 5 more
- Volunteers
- 81 people
- Sponsor
- Pfizer
Gastroesophageal Reflux Disease
Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France
The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI…
- Trial name
- REMAIN (NCT00842855)
- Where
- 44 sites in France
- Volunteers
- 275 people
- Sponsor
- AstraZeneca
Gastro Esophageal Reflux Disease PPI Non-Responders
A Prospective, Observational Study of the PPI Non-responder
Gastroesophageal reflux disease (GERD) is a common chronic condition, affecting approximately 20% of the American adult population. Proton pump inhibitors (PPIs) are now the mainstay of medical therapy for symptoms of GERD.
- Trial name
- NCT03282084
- Testing
- EGD with biopsy, EGD and impedance-pH study on PPI
- Sponsor
- Dartmouth-Hitchcock Medical Center